FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Arcutis received FDA approval for a supplemental indication of ZORYVE cream 0.3%, expanding its use to treat plaque psoriasis in children as young as 2 years of age. The approval is supported by data from a 4-week maximal usage systemic exposure study and an open-label extension study demonstrating safety and efficacy profiles consistent with pivotal trials in older patients.
Key figures
- Drug Name
- ZORYVE (roflumilast) cream 0.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.